Corient Private Wealth LP Purchases Shares of 1,748,739 Stryker Corporation $SYK

Corient Private Wealth LP acquired a new position in Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 1,748,739 shares of the medical technology company’s stock, valued at approximately $323,035,000. Corient Private Wealth LP owned about 0.46% of Stryker at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Varma Mutual Pension Insurance Co lifted its position in shares of Stryker by 10.5% in the fourth quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock worth $18,842,000 after buying an additional 5,100 shares during the last quarter. QRG Capital Management Inc. increased its holdings in shares of Stryker by 7.4% during the 4th quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock valued at $21,281,000 after acquiring an additional 4,186 shares during the last quarter. Swedbank AB raised its stake in shares of Stryker by 6.6% in the 4th quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock valued at $45,349,000 after acquiring an additional 7,934 shares in the last quarter. Crossmark Global Holdings Inc. lifted its holdings in Stryker by 31.1% in the 4th quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock worth $9,426,000 after purchasing an additional 6,367 shares during the last quarter. Finally, Royal Bank of Canada boosted its position in Stryker by 6.5% during the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after purchasing an additional 199,863 shares during the period. 77.09% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

SYK has been the subject of a number of analyst reports. The Goldman Sachs Group restated a “neutral” rating and issued a $361.00 price objective on shares of Stryker in a research note on Friday, May 1st. Wells Fargo & Company lowered their target price on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Evercore set a $350.00 target price on shares of Stryker in a research report on Monday, July 6th. Citigroup restated a “buy” rating on shares of Stryker in a report on Thursday, August 13th. Finally, Raymond James Financial set a $370.00 price target on Stryker in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Trading Down 0.2%

Stryker stock opened at $330.08 on Thursday. The business has a 50 day moving average price of $328.37 and a two-hundred day moving average price of $331.72. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The stock has a market cap of $126.61 billion, a price-to-earnings ratio of 34.21, a price-to-earnings-growth ratio of 2.11 and a beta of 0.76. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter last year, the firm earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts forecast that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is 36.48%.

Insiders Place Their Bets

In other Stryker news, insider Dylan Bram Crotty sold 441 shares of the business’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the sale, the insider owned 6,102 shares of the company’s stock, valued at $2,005,178.22. The trade was a 6.74% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Ronda E. Stryker sold 50,000 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the completion of the sale, the director directly owned 2,251,375 shares in the company, valued at $765,692,637.50. This trade represents a 2.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 351,267 shares of company stock worth $118,197,701 over the last 90 days. Corporate insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.